Promising results for the use of catabolic enzyme inhibitors in post-traumatic stress disorder

GlobalData Healthcare 4th September 2019 (Last Updated September 4th, 2019 16:03)

The pipeline for PTSD includes several therapies intended to be administered alongside psychotherapy to maximise positive outcomes for patients with common comorbidities such as anxiety and depression.

Promising results for the use of catabolic enzyme inhibitors in post-traumatic stress disorder

The interplay of psychotherapy and pharmacology in treating mental health conditions such as post-traumatic stress disorder (PTSD) has long been a point of focus for scientific researchers and drug developers alike. 

The pipeline for PTSD includes several therapies intended to be administered alongside psychotherapy to maximise positive outcomes for patients with common comorbidities such as anxiety and depression.

The National Institute on Alcohol Abuse’s AM-3506 and Sanofi’s SAR-411298 are both at the pre-clinical stage of development for PTSD. These drugs work by blocking a catabolic enzyme known as fatty acid amide hydrolase (FAAH). This enzyme breaks down fatty acid amides including oleamide, N-acyltaurines, N-acylethanolamines, and certain endocannabinoids.

Anandamine is an endocannabinoid and neurotransmitter that can exhibit numerous effects in the central nervous system (CNS). As a psychoactive lipid, anandamide is known to play a role in memory consolidation, regulation of feeding behaviour, and motivation and reward pathways. Low levels of anandamine have been linked to anxiety and increased sensitivity to pain. 

Research into treating psychiatric disorders such as PTSD and anxiety has led to the development of therapeutics that target FAAH, the enzyme that breaks down anandamine. In a randomized, placebo-controlled, double-blind experimental study coordinated by researchers at Linköping University in Sweden, healthy participants were given SpringWorks Therapeutics’ PF-0445784. PF-0445784 is being developed for drug addiction, which is a common comorbidity in PTSD. Before this, participants were conditioned to associate an unpleasant sound with a predetermined colour as a way for researchers to mimic the physiological mechanisms that induce symptoms such as hyperarousal, hypervigilance, and tachycardia that are often seen in patients living with PTSD. 

Treatment with PF-0445784, which inhibits FAAH, the enzyme that breaks down anandamine, was given over 10 days. Physiological signs of stress such as elevated cortisol levels were traced by investigators, who found that hyperarousal in the presence of the colour associated with the unpleasant sound was reduced in participants who received PF-0445784. In this way, participants were able to unlearn the behavioural patterns that linked the unpleasant noise with the specific colour used in the study. Therefore, it was concluded that inhibiting FAAH may have promise in treating PTSD alongside assistive psychotherapy, which is the first-line treatment offered to patients all over the world.

GlobalData estimated the value of the PTSD pharmacotherapy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) to be $211.4m in 2018, excluding the sales of off-label therapeutics. The PTSD market is expected to grow to reach $1.2bn by 2028 in the 7MM. Although FAAH inhibitors are at an early stage of development for PTSD, their antihypertensive effects and ability to reduce sympathetic muscle tone show promise for treating both CNS and non-CNS indications, such as emesis and DiGeorge syndrome. 

Related Report

GlobalData (2016). PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025, October 2016, GDHC126PIDR